The folks at GlaxoSmithKline must be celebrating today: Rival Novartis has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about.
GSK chief Andrew Witty has been pooh-poohing the potential of generic rivals to that best-selling lung [...]

Popularity: 1% [?]

The complex legislative maneuvering to pass health-care overhaul legislation has produced many questions and among them this: When can the White House declare victory?
If the House passes the Senate health bill on Sunday, as Democrats hope, and President Obama signs it into law, the overhaul will be official -– signed, sealed and delivered. But the [...]

Popularity: 1% [?]

Why do Americans pay so much for their pharmaceuticals? That’s the question posed by Sen. Herb Kohl, a Democrat and chairman of the Senate Special Committee on Aging, who has written to the world’s top drugmakers to demand an explanation.
“Americans pay, on average, twice as much as people in other industrialized countries,” Chairman Kohl states [...]

Popularity: 1% [?]

Roche has tipped investors on all the key talking points ahead of today’s pipeline review. In a statement released early today, Roche noted that it is positioned to launch six new therapies by the end of 2014 and wants to push beyond cancer therapies and into new arenas, such as metabolism, inflammation and the central [...]

Popularity: 1% [?]

It’s been a bad month for Pfizer’s research labs but its head of R&D says the world’s biggest drugmaker is on track to hit earlier targets for new drug filings despite the setbacks.
“We have had some disappointments, there is no getting away from it,” Martin Mackay told Reuters during a visit to Britain.
Dimebon’s lack of [...]

Popularity: 1% [?]

Sanofi-Aventis and its female sales reps in the U.S. have come to a deal. The drugmaker has agreed to pay $15.4 million to settle a class-action discrimination suit that alleges Sanofi underpaid and underpromoted its female reps.
The settlement agreement also requires Sanofi to analyze its sales-rep compensation and, wherever disparities between men and women are found, [...]

Popularity: 1% [?]

Roche investors are expected to pay particularly close attention at tomorrow’s pipeline review day, when top execs for the pharma giant will try to put the best face possible on its new drug prospects.
This is the first pipeline review since Roche absorbed Genentech, and analysts will be looking to see whether the pharma giant’s recent [...]

Popularity: 1% [?]

Researchers at Philadelphia’s Wistar Institute have identified a gene that may regulate regeneration in mammals. According to their research, the absence of the p21 gene confers a healing potential in mice long thought to be reserved for creatures like flatworms, sponges and some species of salamander. But in a report published in the Proceedings of the [...]

Popularity: 1% [?]

Biotech companies in the UK are keen to enter into collaborations with India, especially in the areas of pre-clinical and marketing services.
In this connection six companies Stabilitech, Ionscope, Antoxis, Karus Therapeutics, Oxford BioMedica and Chroma Therapeutics are here in India to scout for opportunities with Indian companies. The companies are part of the BioIndustry Association [...]

Popularity: 1% [?]

NGM Biopharmaceuticals today announced it has closed the first tranche of a $51 million Series B round of financing with the help of Column Group, Tichenor Ventures, Prospect Venture Partners, Rho Ventures and other new and existing investors. The South San Francisco-based company, which was founded in 2008, also announced the appointment of McHenry Tichenor, Jr., [...]

Popularity: 1% [?]